Strong Liquidity and Financing Availability
Reported liquidity of $653 million at quarter-end (including $135M cash and $500M undrawn revolver) with total financing availability of $7.2 billion (including $2.6B undrawn capacity); management expects over $500M of capital to invest driven by ~ $2 billion of expected repayments in 2026.
Active Portfolio Repositioning and New-Vintage Target
Plan to have loans originated between 2024–2026 represent ~50% of the portfolio by year-end, signaling significant turnover into newer vintage, higher-quality assets; already originated $184M in Q1 and closed/circled >$400M of new loans in the first 3 weeks of Q2.
Mountain View Lease and REO Monetization Opportunity
Signed a long-term full-property lease in Mountain View (tenant: OpenAI) and expects to bring the asset to market in 12–16 months; management estimates monetizing REO assets could generate >$0.15 per share of incremental quarterly earnings over time, nearly half driven by Mountain View.
Office Loan Refinance at Par and Reduction Targets
Refinanced largest office loan ($225M in Bellevue) at par via CMBS SASB transaction; management targeting legacy office exposure reduction from 21% to under 10% (a >11 percentage-point reduction target).
Capital Allocation Tools: Dividend Framework and Buyback
Board authorized a $75M share repurchase program; dividend reset to $0.10 per quarter (from $0.25) to preserve capital optionality for repurchases and new originations while aiming for annualized dividend coverage (~$0.40/year covered by earnings excluding realized losses).
Risk Management and Reserve Actions
Recorded CECL provisions of $74M this quarter (bringing total allowance to $260M) and materially increased reserves for the Seaport loan; life science exposure modified increased from 19% to 30% this quarter (an +11 percentage-point improvement including the Cambridge asset).
Stable Funding Profile and Leverage Discipline
77% of financing is non-mark-to-market, providing stability; no final facility maturities until 2027 and no corporate debt due until 2030; debt-to-equity ratio 2.2x and total leverage at 4x, consistent with target range.